Literature DB >> 26159672

Role of innate immune system in systemic sclerosis.

Nicola Fullard1, Steven O'Reilly.   

Abstract

Recognition of microbial or viral compounds is crucial to elicit an immune response and pattern recognition receptors (PRRs) form the first line of defence. An important family of PRRs are the Toll-like receptors (TLRs) with numerous evidences indicating their crucial role in identifying microbial or viral compounds. However, the danger theory, where the innate immune system responds to danger signals such as proteins released during damage or necrosis rather than only non-self is gaining ground. Indeed, TLRs are able to recognise endogenous molecules and have been implicated as key players in numerous autoimmune diseases including systemic sclerosis (SSc). TLR2 is known to be upregulated in SSc and has been shown to respond to the endogenous ligand amyloid A resulting in increased IL-6 secretion. TLR4 is now known to respond to a variety of endogenous ligands including fibronectin, containing alternatively spliced exons encoding type III repeat extra domain (EDA). EDA is only expressed upon tissue damage, and elevated levels can be found in SSc patients, idiopathic pulmonary fibrosis and cardiac allograft fibrosis, while deletion of EDA or TLR4 in mice reduces their fibrotic response. Further, stimulation of TLR8 with single-stranded RNA leads to increased expression of TIMP-1. This has been shown to require both IRAK4 and NF-κB with evidence suggesting autoantibodies bind to RNA to stimulate TIMP-1 production in monocytes. Therefore, TLR-mediated signalling provides numerous potential therapeutic targets for development of therapies for the treatment of multi-systemic autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26159672     DOI: 10.1007/s00281-015-0503-7

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  60 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

2.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.

Authors:  Kim Midwood; Sandra Sacre; Anna M Piccinini; Julia Inglis; Annette Trebaul; Emma Chan; Stefan Drexler; Nidhi Sofat; Masahide Kashiwagi; Gertraud Orend; Fionula Brennan; Brian Foxwell
Journal:  Nat Med       Date:  2009-06-28       Impact factor: 53.440

3.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

4.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Rheum       Date:  2011-11

5.  Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis.

Authors:  S S Lok; J P Stewart; B G Kelly; P S Hasleton; J J Egan
Journal:  Respir Med       Date:  2001-10       Impact factor: 3.415

6.  Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A.

Authors:  Ni Cheng; Rong He; Jun Tian; Patrick P Ye; Richard D Ye
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

Review 8.  Role of toll-like receptors in systemic sclerosis.

Authors:  Marzena Ciechomska; Rachel Cant; James Finnigan; Jacob M van Laar; Steven O'Reilly
Journal:  Expert Rev Mol Med       Date:  2013-08-28       Impact factor: 5.600

9.  miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses.

Authors:  Gang Liu; Arnaud Friggeri; Yanping Yang; Young-Jun Park; Yuko Tsuruta; Edward Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-31       Impact factor: 11.205

10.  TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy.

Authors:  Jin Ma; Steven J Chadban; Cathy Y Zhao; Xiaochen Chen; Tony Kwan; Usha Panchapakesan; Carol A Pollock; Huiling Wu
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more
  26 in total

1.  Connective tissue diseases: Nucleosomes and systemic sclerosis.

Authors:  Steven O'Reilly; Jacob M van Laar
Journal:  Nat Rev Rheumatol       Date:  2016-02-04       Impact factor: 20.543

Review 2.  Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.

Authors:  Medya M Shikhagaie; Kristine Germar; Suzanne M Bal; Xavier Romero Ros; Hergen Spits
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

3.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

4.  Integrin α4β1 and TLR4 Cooperate to Induce Fibrotic Gene Expression in Response to Fibronectin's EDA Domain.

Authors:  Rhiannon M Kelsh-Lasher; Anthony Ambesi; Ceyda Bertram; Paula J McKeown-Longo
Journal:  J Invest Dermatol       Date:  2017-08-24       Impact factor: 8.551

Review 5.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

Review 6.  Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential.

Authors:  Pei-Suen Tsou; John Varga; Steven O'Reilly
Journal:  Nat Rev Rheumatol       Date:  2021-09-03       Impact factor: 20.543

7.  [Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment].

Authors:  X B Ma; X W Zhang; R L Jia; Y Gao; H J Liu; Y F Liu; Y N Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-18

8.  Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.

Authors:  Tamer A Gheita; Safaa Sayed; Gada S Azkalany; Nouran Abaza; Nevin Hammam; A H Eissa
Journal:  Clin Rheumatol       Date:  2017-10-26       Impact factor: 2.980

Review 9.  Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.

Authors:  Swati Bhattacharyya; John Varga
Journal:  Immunol Lett       Date:  2017-09-28       Impact factor: 3.685

10.  Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Authors:  Fabian A Mendoza; Maryah Mansoor; Sergio A Jimenez
Journal:  Expert Opin Orphan Drugs       Date:  2015-11-23       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.